New Pharmaceutical Candidate Enters Lundbeck's Development Pipeline

Lundbeck has initiated clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug.

H. Lundbeck A/S (Lundbeck), a Copenhagen-based pharmaceutical company, strengthens its pipeline of pharmaceuticals in clinical development by initiating clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.

Lu AF11167 is a new compound inhibiting a phosphodiesterase enzyme primarily expressed in brain and here in regions relevant for a number of both neurological and psychiatric diseases in humans. By inhibiting this enzyme, Lu AF11167 boosts signalling and thus increases the activity of certain neurons in the brain.

Extensive research in animals suggests that these type of compounds have potential in e.g. Alzheimer's disease, Huntington's chorea and schizophrenia.